The impact of hormone replacement therapy on metabolic syndrome components in perimenopausal women

This publication has 21 references indexed in Scilit:

• Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause
  JAMA, 2007
• Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists
  European Heart Journal, 2007
• Updating the EMAS 2004/2005 clinical recommendations on postmenopausal therapy following the recent publications: WHI and Nurses’ Health Study
  Maturitas, 2006
• American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for The Diagnosis and Treatment Of Menopause
  Endocrine Practice, 2006
• Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation
  Diabetic Medicine, 2006
• Hormone Therapy and Coronary Heart Disease: The Role of Time since Menopause and Age at Hormone Initiation
  Journal of Women's Health, 2006
• The ORlistat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORliCARDIA) study
  Current Medical Research and Opinion, 2004
• Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society: Retracted
  Menopause, 2004
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report
  Circulation, 2002
• Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation
  Diabetic Medicine, 1998